A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
Inclusion Criteria:
Exclusion Criteria:
Medical Conditions
Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.
History of thymectomy within the 12 months prior to screening.
History of N meningitidis infection.
Use of the following within the time period specified below:
Participants who have received previous treatment with complement inhibitors (for example, eculizumab).
Arhus C, 8000, Denmark
Hanamaki-shi, 025-0075, Japan
Kawagoe-shi, 350-8550, Japan
Moriguchi-shi, 570-8507, Japan
Shinjuku-ku, 160-8582, Japan
Ube-shi, 755-8505, Japan